|
Schizophrenia
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Increased plasma glutamate by antipsychotic medication and its relationship to glutaminase 1 and 2 genotypes in schizophrenia -- Juntendo University Schizophrenia Projects (JUSP).
|
17669570 |
2007 |
|
Schizophrenia
|
0.340 |
Biomarker
|
disease |
BEFREE |
Strikingly, mice deficient in the glutamate synthetic enzyme glutaminase have CA1 hypoactivity and a SCZ-resilience profile, implicating glutamate-metabolizing enzymes.
|
29471549 |
2019 |
|
Schizophrenia
|
0.340 |
Biomarker
|
disease |
BEFREE |
A constitutive heterozygous reduction in GLS1 engenders in mice a model of schizophrenia resilience and associated increases in Gln, reductions in Glu and activity-dependent attenuation of excitatory synaptic transmission.
|
31326460 |
2019 |
|
Schizophrenia
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Studies of the glutamate metabolic pathway have been limited, although there is some evidence that excitatory amino acid transporter-2, glutamine synthetase, and glutaminase have altered expression in schizophrenia.
|
25315318 |
2015 |
|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Degenerative polyarthritis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mitochondrial dysregulation of osteoarthritic human articular chondrocytes analyzed by proteomics: a decrease in mitochondrial superoxide dismutase points to a redox imbalance.
|
18784066 |
2009 |
|
Osteoarthrosis Deformans
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mitochondrial dysregulation of osteoarthritic human articular chondrocytes analyzed by proteomics: a decrease in mitochondrial superoxide dismutase points to a redox imbalance.
|
18784066 |
2009 |
|
Miscarriage
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression in cultured endometrium from women with different outcomes following IVF.
|
18539642 |
2008 |
|
Epileptic encephalopathy
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
|
Epileptic encephalopathy
|
0.110 |
Biomarker
|
disease |
BEFREE |
Early neonatal epileptic encephalopathy with glutaminase deficiency and lethal outcome.
|
30575854 |
2019 |
|
Global developmental delay
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
|
Global developmental delay
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
We report a de novo Ser482Cys gain-of-function variant in GLS encoding GLS associated with profound developmental delay and infantile cataract.
|
30239721 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Triple-negative (TN) breast cancer (testing negative for estrogen, progesterone, and Her2 receptors) has elevated GLS protein levels and reportedly depends on exogenous glutamine and GLS activity for survival.
|
31541193 |
2020 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results demonstrate in a mouse model of breast cancer the utility of GluCEST MRI to detect the early response to glutaminase inhibition.<b>Significance:</b> A sensitive method enables noninvasive detection of tumor response to inhibitors of glutamine metabolism.<i></i>.
|
30072394 |
2018 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, knockdown or inhibition of GLS1 significantly decreased the proliferation of breast cancer cells with high GLS1 levels.
|
24122876 |
2014 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The first complete sequence of human L-glutaminase was deduced from breast cancer glutaminase cDNA cloned in our laboratory.
|
12758143 |
2003 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumors of this subtype had a stem cell-like transcriptional signature and tended to overexpress glutaminase, suggestive of a functional relationship between glutamine and 2HG metabolism in breast cancer.
|
24316975 |
2014 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of non-invasive epithelial (T-47D and MDA-MB-361) and invasive mesenchymal (MDA-MB-231 and Hs-578T) breast cancer cell lines with the glutaminase inhibitor, Compound 968, resulted in cytotoxicity in all cell lines, with the greatest effect being observed in MDA-MB-231 breast cancer cells.
|
23117580 |
2012 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>13</sup>C HR MAS MRS analysis of tumor tissue from CB-839-treated and untreated models receiving <sup>13</sup>C-labeled glutamine ([5-<sup>13</sup>C] Gln) shows that the glutaminase inhibitor CB-839 is causing an accumulation of glutamine (arrow up) in two PDX models representing luminal-like breast cancer (MAS98.06) and basal-like breast cancer (MAS98.12).
|
31088535 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blocking the conversion of glutamine to glutamate using an allosteric inhibitor, Compound 968, against GLS1, increased H4K16ac in T-47D and MDA-MB-231 cells, linking glutamine metabolism to a particular histone modification in breast cancer.
|
22101407 |
2012 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, [<sup>18</sup>F]4F-Gln PET tracked cellular glutamine pool size in breast cancers with differential GLS activity and detected increases in cellular glutamine pool size induced by GLS inhibitors.
|
28202527 |
2017 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of MYC, SLC1A5 and GLS decreased AI resistant breast cancer cell proliferation.
|
25683269 |
2015 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Molecular cloning, sequencing and expression studies of the human breast cancer cell glutaminase.
|
10620514 |
2000 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transcriptional analyses revealed that the expression levels of genes linked to lipid metabolism were altered between sensitive and resistant cells and between breast cancer tissues (available from The Cancer Genome Atlas project) with low <i>versus</i> high glutaminase (<i>GLS</i>) gene expression.
|
31040181 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study has identified GLS a potential therapeutic target in breast cancer, specifically in the basal subtype that exhibits a deregulated glutaminolysis pathway.
|
28950000 |
2017 |